BioCentury
ARTICLE | Company News

Second Vertex drug caught in CF standoff

August 9, 2018 9:23 PM UTC

NICE's suspension of its review of Symkevi tezacaftor/ivacaftor on Thursday marks the latest delay of access in England and Wales to cystic fibrosis drugs from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX).

NICE suspended its review after the company did not provide an evidence submission, according to the committee's website. It also canceled plans to discuss Symkevi's appraisal at a Nov. 8 meeting...